

PRESS RELEASE

FOR IMMEDIATE RELEASE:

Ocutronics Awarded Qualifying Therapeutic Discovery Project Grant

Los Angeles, California, (September 1, 2010) – Ocutronics, LLC, developer of a unique new retinal camera for diagnosis of eye disease, was awarded a grant by the IRS in its Qualifying Therapeutic Discovery Project Program.

Ocutronics was awarded \$244,000, from the federal government, the largest amount possible under this program. The funds are to be used to continue development work on Ocutronics' new technology for retinal imaging to help reduce the costs and severity of diabetic retinopathy..

Ocutronics' technology allows a paradigm shift in the way retinal photographs are taken, making it possible to do much wider screening of diseases like diabetic retinopathy, macular degeneration, and hypertensive retinopathy. There are over 250 million diagnosed diabetics in the world and 80% will get diabetic retinopathy. If not treated, 250,000 will go blind every year. Diabetes is the leading cause of blindness among working adults. Broader screening can allow earlier treatment to prevent blindness and greatly reduce the costs of care. Ocutronics' camera can make screening much more accessible than ever before.

Ocutronics, located in Los Angeles, California, is a development-stage company that has patented technology for a new retinal camera that has numerous advantages over traditional retinal cameras. It can be used without dilating drops, since it can take pictures through a 2mm diameter pupil, versus others' 3.85mm. It is very light, portable and extremely easy to use. Its very low light output is very comfortable for patients. The images from the camera are stored "on the cloud" in a comprehensive health records management system.

Contact:

Bill Collins, CEO

Bill@Ocutronics.com

www.Ocutronics.com.

720-334-1429